A5102874437- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Cardiac Arrest and Resuscitation
- Transplantation: Methods and Outcomes
- Cardiac pacing and defibrillation studies
- Organ Transplantation Techniques and Outcomes
- Fuel Cells and Related Materials
- Cardiac and Coronary Surgery Techniques
- Cardiac Ischemia and Reperfusion
- Viral Infections and Immunology Research
- Signaling Pathways in Disease
- Cardiac Valve Diseases and Treatments
- Atrial Fibrillation Management and Outcomes
- Heart Failure Treatment and Management
- Congenital Heart Disease Studies
- Renal Transplantation Outcomes and Treatments
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Infectious Aortic and Vascular Conditions
- Venous Thromboembolism Diagnosis and Management
- Aortic Disease and Treatment Approaches
- Cardiac Fibrosis and Remodeling
- Surgical site infection prevention
- Ultrasound in Clinical Applications
- Long-Term Effects of COVID-19
Harefield Hospital
2014-2024
National Health Service
2006-2024
Advanced Circulatory System (United States)
2023
Guy's and St Thomas' NHS Foundation Trust
2021-2023
Royal Brompton & Harefield NHS Foundation Trust
2010-2020
NIHR Royal Brompton Cardiovascular Biomedical Research Unit
2020
Penn State Milton S. Hershey Medical Center
2016
Imperial College London
2005-2015
University of Louisville
2011
National Institutes of Health
2010
In patients with severe heart failure, prolonged unloading of the myocardium use a left ventricular assist device has been reported to lead myocardial recovery in small numbers for varying periods time. Increasing frequency and durability could reduce or postpone need subsequent transplantation.
Background— We have previously shown that a specific combination of drug therapy and left ventricular assist device unloading results in significant myocardial recovery, sufficient to allow pump removal, two thirds patients with dilated cardiomyopathy receiving Heartmate I pulsatile device. However, this protocol has not been used nonpulsatile devices. Methods Results— report the prospective study 20 who received angiotensin-converting enzymes, β-blockers, angiotensin II inhibitors,...
Abstract The SERCA-LVAD trial was a phase 2a assessing the safety and feasibility of delivering an adeno-associated vector 1 carrying cardiac isoform sarcoplasmic reticulum calcium ATPase (AAV1/SERCA2a) to adult chronic heart failure patients implanted with left ventricular assist device. one program AAV1/SERCA2a gene therapy trials including CUPID1, CUPID 2 AGENT trials. Enroled subjects were randomised receive single intracoronary infusion × 10 13 DNase-resistant particles or placebo...
The purpose of this prospective study was to evaluate the effects and functional outcome central extracorporeal life support (ECLS) with left ventricular decompression for treatment refractory cardiogenic shock lung failure.Between August 2010 2013, 12 consecutive patients (2 female) a mean age 31.6 ± 15.1 years received ECLS failure. Underlying disease acute cardiac decompensation due dilated cardiomyopathy (n = 3, 25%), coronary artery myocardial infarction (AMI) myocarditis 6, 50%). We...
An implantable left ventricular assist device (LVAD) is indicated as a bridge to transplantation or recovery in the United Kingdom (UK). The mechanism of action LVAD results unique state haemodynamic stability with diminished arterial pulsatility. clinical assessment an recipient can be challenging because non-invasive blood pressure, pulse and oxygen saturation measurements may hard obtain. As result this unusual situation complex interplay between native circulation, resuscitation...
Abstract The aim of this study was to elucidate the dynamic characteristics T horatec H eart M ate II ( HMII ) and W are HVAD left ventricular assist devices LVADs under clinically representative in vitro operating conditions. performance two were compared a normothermic, human blood‐filled mock circulation model conditions steady (nonpulsatile) flow simulated physiologic These experiments repeated using 5% dextrose order determine its suitability as blood analog. Under conditions, for ,...
Background We evaluated the potential benefits of renin‐angiotensin‐aldosterone system inhibitors (RAASi) in patients with left ventricular assist device support. Methods and Results A total 165 consecutive undergoing implant alive at 6‐month on support were studied. RAASi status after visit along clinical reasons for nonprescription/uptitration retrospectively assessed. The primary outcome was a composite heart failure hospitalization or cardiovascular death between 6 24 months implant....
Molecular mechanisms underlying the deterioration of patients undergoing LV assist device (LVAD) implantation remain poorly understood. We studied cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta IL-6 terminal stage apoptotic pathway in with decompensating heart failure who required LVAD support compared them less severe elective transplantation.Myocardial serum samples from 23 were those 36 transplantation. Myocardial TNF-alpha mRNA (1.71-fold; P<0.05) protein...
Journal Article Development of mock circulation models for the assessment counterpulsation systems Get access Christopher T Bowles, Bowles Correspondence to: C Search other works by this author on: Oxford Academic PubMed Google Scholar Samir S Shah, Shah Kazunobu Nishimura, Nishimura Colin Clark, Clark Deborah V E Cumming, Cumming Charles W Pattison, Pattison John R Pepper, Pepper Magdi H Yacoub Cardiovascular Research, Volume 25, Issue 11, November 1991, Pages 901–908,...